P1.060. Long-Term Outcome of Adjuvant Chemoradiotherapy (CRT) Plus Pembrolizumab in Resectable Esophageal Squamous Cell Carcinoma (ESCC) at High Risk of Recurrence
Clicks: 2
ID: 325773
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.3
/100
2 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #116 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background Adjuvant chemoradiotherapy followed by pembrolizumab (NCT03322267) has been shown to reduce relapses in patients at high risk of recurrence, including those with involved or close margins (≤1 mm), compared with a historical control cohort. This study evaluated long-term outcomes of this regimen. Methods Patients with resectable ESCC harboring high-risk recurrence features in tumor tissues after neoadjuvant chemoradiotherapy and esophagectomy—including involved or close margins (≤1 mm), extranodal extension of involved lymph nodes, or ypN2–3 disease—were enrolled in a single-arm phase II trial evaluating adjuvant cisplatin-based chemoradiotherapy (30 mg/m2 intravenously weekly for two cycles; 180–200 cGy per fraction for 10–13 fractions) followed by pembrolizumab (200 mg intravenously every 3 weeks for 18 cycles). A contemporary cohort with similar high-risk features was identified from a randomized phase II trial (NCT03623737). Progression-free survival (PFS), defined as the time from radical esophagectomy to disease recurrence or death, and overall survival (OS), defined as the time from radical esophagectomy to death, were compared between groups after long-term follow-up, with data locked on 1 December 2025. Survival outcomes were analyzed using the log-rank test, and baseline characteristics were summarized using descriptive statistics. Results From March 2017 to May 2024, 25 patients in the pembrolizumab cohort and 18 in the contemporary cohort were enrolled, with comparable median follow-up durations (59.4 vs 78.4 months). Baseline characteristics were generally balanced between groups, except for a higher proportion of lower post-neoadjuvant therapy stage and fewer patients receiving adjuvant CRT in the control group (P = 0.069 and 0.001, respectively). A trend toward improved median PFS was observed in the pembrolizumab cohort compared with controls (15.5 vs 5.3 months; P = 0.064; hazard ratio [HR], 0.53; 95% CI, 0.25–1.13), as well as improved median OS (22.9 vs 12.3 months; P = 0.066; HR, 0.52; 95% CI, 0.24–1.13). Subgroup analyses further demonstrated trends toward improved survival among patients with involved or close resection margins (≤1 mm), those who received adjuvant CRT, and those who were not enrolled in the randomized phase II trial. Conclusion Although there is potential selection bias from control cohort, adjuvant cisplatin-based chemoradiotherapy followed by one year of pembrolizumab demonstrated trends toward improved survivals in patients with residual pathologic disease and high-risk features after trimodality therapy for locally advanced ESCC (funded by Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc, Kenilworth, NJ (T.K.) [MISP# 55717] and NCTRC201703).
| Reference Key |
openalex_W7203931722
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Jhe‐Cyuan Guo, Ta‐Chen Huang, Chien-Huai Chuang, Hung‐Yang Kuo, Chia-Chi Lin, Tsung‐Che Wu, Jang‐Ming Lee, Chih‐Hung Hsu |
| Journal | diseases of the esophagus : official journal of the international society for diseases of the esophagus |
| Year | 2026 |
| DOI |
10.1093/dote/doag077.208
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.